HCApna Reclassification and Coding
I need to clarify that the term "HCApna" appears to be unclear or potentially a typographical error. However, based on the context of your question and the available evidence, I can address what appears to be the most relevant topic: hydrocodone-acetaminophen (HCA) combination products have been reclassified from DEA Schedule III to Schedule II controlled substances.
DEA Schedule Reclassification
Hydrocodone combination products (such as Vicodin, Lortab, and Norco) were reclassified from Schedule III to Schedule II controlled substances, effective October 6,2014 1, 2.
Key Points About the Reclassification:
Prior Classification: Hydrocodone combined with acetaminophen (15 mg or less hydrocodone per dose) was classified as Schedule III 1
Current Classification: All hydrocodone-containing products are now Schedule II controlled substances 2
Rationale: The reclassification occurred in response to increasing levels of abuse of these substances and concerns about their abuse potential 1
Additional FDA Requirement: The FDA also limited the acetaminophen component to 325 mg or less per pill to reduce hepatotoxicity risk 1, 2
Coding Implications
For prescription and documentation purposes:
- Schedule II designation means stricter prescribing requirements including:
- No refills permitted (new prescription required for each fill)
- Written or electronic prescriptions required in most states
- More stringent record-keeping requirements
- Limited prescription quantities (typically 30-day supply maximum)
Clinical Context
Hydrocodone remains the most commonly prescribed opioid in the United States, with over 135 million prescriptions in 2012, and the U.S. consumes 99% of the global supply 2. The reclassification was implemented as part of efforts to address the opioid abuse epidemic while maintaining access for legitimate pain management 2.
If "HCApna" refers to a different medication or coding system, please provide additional clarification for a more specific answer.